C4X Discovery Holdings PLC Result of General Meeting and Issue of Equity (1703B)
March 31 2017 - 4:42AM
UK Regulatory
TIDMC4XD
RNS Number : 1703B
C4X Discovery Holdings PLC
31 March 2017
C4X Discovery Holdings plc
("C4XD" or the "Company")
Result of General Meeting
and
Issue of Equity
31 March 2017 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering drug discovery company, today announces that, at the
General Meeting held earlier today in respect of its GBP7.0m
Placing at a Placing Price of 85 pence per new Ordinary Share,
which was announced to the market on 14 March 2017, all the
resolutions put to shareholders were duly passed.
Application has been made for the 8,235,294 Placing Shares to be
admitted to trading on AIM and it is expected that Admission will
take place at 8.00 a.m. on 3 April 2017. The Placing Shares will
rank pari passu with the existing Ordinary Shares.
Following Admission, the Company's issued share capital will
consist of 45,634,012 Ordinary Shares. There are no Ordinary Shares
held in treasury. Therefore, in accordance with the FCA's
Disclosure and Transparency Rule 5.6.1, the Company confirms that
following Admission, the total number of voting rights in the
Company will be 45,634,012.
The capitalised terms used in this announcement have the meaning
as defined in the announcement published by the Company at 7.00
a.m. on 14 March 2017 unless otherwise stated.
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer 07801 865 803
Panmure Gordon (UK) Limited (NOMAD) 020 7886 2500
Freddy Crossley, Duncan Monteith (Corporate Finance)
Tom Salvesen (Corporate Broking)
Consilium Strategic Communications
Mary-Jane Elliott, Matthew Neal, Melissa Gardiner 0203 709
5700
About C4X Discovery
C4X Discovery aims to become the world's most productive drug
discovery engine by exploiting cutting edge technologies to design
and create best-in-class small-molecule candidates targeting a
range of high value therapeutic areas. The company's goal is to
drive returns through early-stage revenue-generating deals with the
pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary
technologies across the drug discovery process. The company's
innovative DNA-based target identification platform (Taxonomy3(R))
utilises human genetic datasets to identify novel patient-specific
targets leading to greater discovery productivity and increased
probability of clinical success. This is complemented by C4XD's
novel drug design platform which comprises two innovative chemistry
technologies, Conformetrix and Molplex, that combine 4D molecular
shape analyses (based on experimental data) with best-in-class
computational chemistry. This provides new and unprecedented
insight into the behaviour of drug molecules, enabling the
production of potent selective compounds faster and more cost
effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline in addiction,
diabetes and inflammation with a number of new drug candidates
identified and further progress made towards the clinic. In
selecting new targets C4X Discovery will focus on the high-value
disease areas of inflammation and neurodegeneration, and will
continue to maximise value from opportunistic areas, for example,
immuno-oncology.
The Company was founded as a spin-out from the University of
Manchester. It has a highly experienced management team and Board
who have delivered significant value creation within the healthcare
sector historically and have enabled C4XD to reach multiple value
inflexion points since IPO. For additional information please go
to: www.c4xdiscovery.com
--ENDS----
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCWGUGCWUPMUBG
(END) Dow Jones Newswires
March 31, 2017 05:42 ET (09:42 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024